Currently, there is an ongoing CF clinical trial in phase1/2 to test the delivery of a drug called MRT5005, which uses lipid nanoparticles to deliver an mRNA encoding the full-length CFTR, to the CF lungs via nebulizer (NTC03375047; https://www.cff.org/Trials/Pipeline/details/10157/MRT5005). This evidence concerns the gene CFTR and cystic fibrosis.